News & Events
Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Proceeds will be used to advance multiple programs in Disc’s hematology pipeline into phase 2 development Financing led by OrbiMed and includes new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital and others CAMBRIDGE, Mass.
More News
Disc Medicine Announces Underwritten Offering of Common Stock
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery,...
read more
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP)...
read more
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
read more